Glenmark Pharmaceuticals reported a consolidated net profit of ₹4.83B for the quarter ended June 30, 2026 (Q1FY27), marking a sharp year-on-year increase from ₹469M in the corresponding period of FY26. The Mumbai-based pharmaceutical company's total revenue from operations rose to ₹40.2B in Q1FY27, compared to ₹32.6B in Q1FY26, reflecting broad-based growth across key markets. This strong bottom-line performance was primarily driven by higher net sales, improved operational efficiencies, and the absence of significant exceptional losses that impacted the prior year's comparatives, offering investors a clear signal of normalized profitability.

The Board of Directors approved the unaudited standalone and consolidated financial results on July 31, 2026, pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors Walker Chandiok & Co LLP issued an unmodified review conclusion on the results. The company also announced that its 48th Annual General Meeting will be held on September 11, 2026, with the record date for dividend entitlement set at August 31, 2026.

Financial Performance Highlights

The following table outlines the key financial metrics for Glenmark Pharmaceuticals on a consolidated basis for Q1FY27 versus Q1FY26:

Regional Revenue Breakdown

Glenmark’s growth was supported by double-digit revenue increases across all major geographies. North America emerged as the fastest-growing region, while India and Emerging Markets also delivered strong performances.

Note: North America revenue includes deferred out-licensing income recognition for ISB 2001. Net of this item, core business growth in North America was 19.8%.

Operational and Strategic Developments

During the quarter, Glenmark transferred its nebulizer brands and intellectual property portfolio to its wholly-owned subsidiary, Glenmark Healthcare Limited, for a cash consideration of ₹2.23B. This transaction was recognized as an exceptional item in the standalone financial results. In India, the formulation business outperformed the industry peer market (IPM), growing by 18.1% compared to IPM growth of 12.2%. Key brands like CANDID® and SCALPE® recorded revenue growth of over 30%.

In North America, Glenmark launched nine new products, including Methylene Blue Injection and Vancomycin Hydrochloride. The company strengthened its respiratory franchise with the first ANDA approval for Fluticasone Propionate Inhalation Aerosol, securing a Competitive Generic Therapy designation. In Europe, WINLEVI® gained traction across multiple markets, including the Nordics and Spain. Emerging Markets saw strong momentum, with Russia’s secondary sales growing by 12% and RYALTRIS® leading in allergic rhinitis treatment.

What the Numbers Show

The surge in net profit is largely attributable to both operational improvement and the absence of significant exceptional losses that impacted the prior year's comparatives. In Q1FY26, the company had recognized exceptional losses related to antitrust settlements and inventory provisions. In contrast, Q1FY27 saw no such consolidated exceptional items, allowing operating profits to flow directly to the bottom line. The EBITDA margin expansion to 19.51% from 17.78% further underscores improved cost management and a favorable revenue mix, particularly given the high-growth contribution from North America and Emerging Markets.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE935A01035/3098ab56-9349-4dd7-b5a1-07719c17f0a2.pdf

Glenmark Pharmaceuticals Inc., USA launched Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials on July 28, 2026, targeting the hospital and institutional segment. The launch positions Glenmark to capture share in a market where the reference listed drug, BRIDION® Injection, 100 mg/mL of Merck Sharp & Dohme LLC, achieved annual sales of approximately $1.6 billion for the 12-month period ending May 2026, according to IQVIA® sales data.

The filing was submitted to the National Stock Exchange of India Limited and BSE Limited under reference number 34/26-27 by Rashmi Khandelwal, Company Secretary & Compliance Officer. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to BRIDION® (NDA 022225). The product is approved only for the indications listed in Glenmark's approved label, which may differ from the approved indications of the reference listed drug.

Product Specifications

The injectable product is available in two strengths, both formulated as single-dose vials at a concentration of 100 mg/mL, as detailed below:

Market Opportunity and Commercial Context

The $1.6 billion annual sales figure for the BRIDION® market, derived from IQVIA® National Sales Perspectives covering retail and non-retail channels, indicates significant commercial potential for Glenmark's new entry. As a therapeutic equivalent, Glenmark's product competes directly with Merck Sharp & Dohme LLC's brand within this high-value injectable category. The data source specifies that IQVIA® figures are available only for all approved RLD indications; therefore, the total addressable market for Glenmark may be narrower if its approved label covers fewer indications than the reference drug.

Marc Kikuchi, President & Business Head, North America, stated that the Day 1 launch reflects execution discipline and agility in Glenmark's injectable strategy. He noted that the addition strengthens the company's presence in the U.S. healthcare system by supporting supply reliability and expanding access to affordable medicines.